Welcome to the trials list!

Some tips to help get started:

  • Click on any trial title to view details, including trial sites, eligibility criteria, and our research about study drugs
  • If the list is long, use the search box and filters on the left to narrow down trials
  • Bookmark trials of interest by clicking the bookmark icon to the right of the trial title
Sign up to save your data! Arrow
Processing... Processing...

Clinical Trials for Non-Small Cell Lung Cancer

Search

Close
[Clear]

Filters

Location:
[Clear]
[Clear]

There are 386 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.

386 trials meet filter criteria.

Sort by:

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Teligene US (industry) Phase: 2 Start date: Dec. 27, 2023

HealthScout AI summary: This trial targets patients aged 18-75 with locally advanced or metastatic NSCLC featuring uncommon EGFR mutations, excluding those previously treated with EGFR-TKIs, and tests Sutetinib maleate, an irreversible EGFR tyrosine kinase inhibitor, for its efficacy and safety.

ClinicalTrials.gov ID: NCT06010329

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Regeneron Pharmaceuticals (industry) Phase: 2/3 Start date: June 30, 2023

HealthScout AI summary: This trial evaluates the efficacy and safety of fianlimab, an anti-LAG-3 antibody, combined with cemiplimab, an anti-PD-1 antibody, compared to cemiplimab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1 ≥50% who have not received prior systemic treatment.

ClinicalTrials.gov ID: NCT05785767

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Teligene US (industry) Phase: 2 Start date: Sept. 1, 2022

HealthScout AI summary: This trial is evaluating the efficacy and safety of Sutetinib Maleate Capsule, an investigational irreversible EGFR tyrosine kinase inhibitor, in adult patients with locally advanced or metastatic NSCLC harboring non-resistant uncommon EGFR mutations (L861Q, G719X, and/or S768I), who have had no more than one prior line of chemotherapy.

ClinicalTrials.gov ID: NCT05168566

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Merck Sharp & Dohme LLC (industry) Phase: 3 Start date: June 10, 2024

HealthScout AI summary: This trial targets adult patients with metastatic squamous non-small cell lung cancer and evaluates the efficacy of pembrolizumab combined with carboplatin and paclitaxel/nab-paclitaxel followed by pembrolizumab with or without the antibody-drug conjugate sacituzumab tirumotecan, which targets TROP2, in improving overall survival.

ClinicalTrials.gov ID: NCT06422143

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: AstraZeneca (industry) Phase: 3 Start date: Oct. 4, 2024

HealthScout AI summary: This trial targets patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer who have progressed after osimertinib treatment, evaluating the efficacy of Dato-DXd, an antibody-drug conjugate targeting TROP2, with or without osimertinib, against standard platinum-based doublet chemotherapy.

ClinicalTrials.gov ID: NCT06417814

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Eikon Therapeutics (industry) Phase: 2 Start date: Feb. 6, 2024

HealthScout AI summary: This trial examines EIK1001, a toll-like receptor 7/8 dual agonist, combined with pembrolizumab and chemotherapy, in adults with stage 4 non-small cell lung cancer who haven't received prior systemic treatment and lack actionable tumor mutations.

ClinicalTrials.gov ID: NCT06246110

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: OncoC4, Inc. (industry) Phase: 3 Start date: June 28, 2023

HealthScout AI summary: This trial involves adult patients with metastatic non-small cell lung cancer (NSCLC) who have progressed after anti-PD-1/PD-L1 therapy and platinum-based chemotherapy, comparing the investigational anti-CTLA-4 antibody gotistobart (ONC-392/BNT316) with docetaxel to evaluate their impact on overall survival.

ClinicalTrials.gov ID: NCT05671510

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: AstraZeneca (industry) Phase: 3 Start date: Nov. 18, 2024

HealthScout AI summary: The trial is evaluating the efficacy of rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, versus pembrolizumab, combined with platinum-based chemotherapy as a first-line treatment for patients with stage IV metastatic squamous non-small cell lung cancer expressing PD-L1 ≥ 1%, excluding those with actionable driver oncogenes.

ClinicalTrials.gov ID: NCT06692738

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: Eli Lilly and Company (industry) Phase: 3 Start date: Dec. 21, 2023

HealthScout AI summary: The trial targets untreated patients with KRAS G12C-mutant, locally advanced or metastatic NSCLC, comparing the efficacy and safety of LY3537982, a KRAS G12C inhibitor, with pembrolizumab, with or without pemetrexed and platinum, against placebo and pembrolizumab regimens. Eligibility varies by PD-L1 expression level: ≥50% for Part A or any level for Part B.

ClinicalTrials.gov ID: NCT06119581

Investigational drug late phase More information Active drug More information Moderate burden on patient More information
Sponsor: AstraZeneca (industry) Phase: 3 Start date: Aug. 3, 2022

HealthScout AI summary: This trial investigates the efficacy of savolitinib, a MET inhibitor, in combination with osimertinib compared to platinum-based chemotherapy in adult patients with EGFR-mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed following osimertinib therapy.

ClinicalTrials.gov ID: NCT05261399

First Previous Page 2 of 39 Next Last
Please help us improve by giving us feedback or feature requests. Email [email protected]
Copy email address
Email copied to clipboard